about
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis CSuccessful Treatment of Necrotizing Fasciitis and Streptococcal Toxic Shock Syndrome with the Addition of LinezolidObservation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains.Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Modelβ-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus.Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus.Current and prospective treatments for multidrug-resistant gram-positive infections.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Shifts in antimicrobial consumption and infection rates before and during a piperacillin-tazobactam shortage.Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia.Ceftazidime/Avibactam: Who Says You Can't Teach an Old Drug New Tricks?Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs.Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application.Mechanisms of Fosfomycin Resistance in Carbapenem-Resistant Enterobacter spp.Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides.Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia.Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent Candida spp.Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetationsThe combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.Ceftriaxone for the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Case Series.Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes.Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.Risk Factors for Failure in Complicated Intraabdominal Infections.Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients.Pronounced heterogeneity observed in high-level daptomycin-resistant viridans group streptococci.Omadacycline Enters the Ring: A New Antimicrobial ContenderComment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditisImpact of Obesity in Patients with Candida Bloodstream Infections: A Retrospective Cohort Study
P50
Q26741123-AC935B60-3496-487B-874E-6E8B1F534BD8Q33440193-36E508F2-822E-4434-8585-B8FD8C9D9DDEQ33939095-F59B727A-F743-42A5-8EE3-AA02F28BE43DQ35678198-A4747EB4-7F30-4BEA-83BE-D18115A7BCA5Q35848781-ED41EDC0-E45F-4686-8FC5-0F9E39334FE2Q35859931-97B5B072-5F0C-40C2-92C0-041D63A626D9Q35974360-B9B190E8-174E-47A0-B9D3-8BA70F8FC4F0Q37023118-E427E568-8EB7-4E2E-80C4-09EC0360B6FFQ37250189-8923F76C-1A9D-4A5E-9F3B-B0ECC08FA85CQ37713010-98EE583C-7B93-4792-9641-0A348FA97175Q37713079-4EDEDB1A-3BC2-4226-A121-FA6B8A947C5EQ38123255-CD202E56-CC9C-41E3-B64E-723B757C4553Q38347869-3A4AC461-CE59-476A-A010-6BFFCA09FD1CQ38642496-20E00227-0675-4AA0-9892-46BB0BD96011Q38679959-5CADB261-BCCE-494C-A636-41355B00306DQ38774448-C04C57B0-9147-4C16-B54B-DF55756013DEQ38949745-8087645E-B0A7-4234-9225-A9670248868CQ39017701-73B7BA92-1881-4D2F-AFF3-4C4297731289Q40143267-74B7063F-4720-4CAF-948A-2DFD219022E6Q40252375-A649CBBC-8177-4C55-9B57-9EC99E130FE9Q40339675-CFF7A032-4E83-4870-8C9F-57535E4EBCE9Q40429884-63D236EC-C161-4563-848E-D4613BE88075Q40947815-E14DB6D2-0EF5-4591-9392-56C0D554C2B3Q41074267-56DA9976-40E5-4D0B-A8D6-BACDA19A98D9Q41832429-BE7432CF-8461-4A42-934E-729EB8F0A7DCQ42217460-5296106A-6C9D-46E9-B7FF-C63F9F9F292CQ42699621-3123CCDE-3FA9-4CAB-9548-698309B103ABQ45938253-5125BFB2-8BBF-477B-B239-1B57D274B2E5Q46104529-BEB949C1-3EA3-4E6B-A685-2899FBC4FFA2Q46178941-B4DB99AE-2B61-4083-BBE5-7A6D36BBBBA3Q48508045-1D1229C9-39F3-4724-AFE8-CB04027390B1Q49445381-036C13FC-9F54-40D2-AB3F-B7B6F921978CQ51068465-98AB8848-A47D-4A73-890B-0BC27380F72FQ56985069-F167E5BC-FD46-44C8-8329-378D3FE1F4A6Q86077663-FCE7B223-B896-40C8-B65C-6BB011B802EBQ89732485-45AB62A9-F59D-4FA9-9305-F54CD3F1F273
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Katie E Barber
@ast
Katie E Barber
@en
Katie E Barber
@es
Katie E Barber
@nl
type
label
Katie E Barber
@ast
Katie E Barber
@en
Katie E Barber
@es
Katie E Barber
@nl
prefLabel
Katie E Barber
@ast
Katie E Barber
@en
Katie E Barber
@es
Katie E Barber
@nl
P106
P1153
55787789300
P21
P31
P496
0000-0002-8411-3111